Singapore, May 5, 2026, 02:01 SGT
- Mobile-health Network Solutions has inked a non-binding US$119 million framework with Hector Capital, connected to its planned acquisitions of BIMA and M&M Helix.
- Just days ago, MNDR unveiled a different data-center financing package worth US$126 million; now, the company is proposing the latest round of funding.
- MNDR shares surged roughly 60% from the previous close. Still, the framework isn’t final—definitive agreements, valuation steps, and approvals remain outstanding.
Mobile-health Network Solutions has entered into a non-binding memorandum of understanding with Hector Capital Holdings, eyeing up to US$119 million in backing for planned majority-stake buys in MILVIK Singapore—also called BIMA—and M&M Helix. The memorandum lays out the intended terms, but it isn’t a finalized deal on its own.
Timing is crucial here. MNDR is pushing to raise fresh capital and build up assets fast, after its auditor flagged recurring losses in an amended annual filing—raising “substantial doubt” over whether the company can keep operating as a going concern. Simply put: without new financing or another solution, paying obligations could become a real issue.
Investors jumped in fast. Shares of Mobile-health Network Solutions on Nasdaq climbed to $1.52, about 60% higher than their prior close at 95 cents, while intraday trading volume approached 99.8 million shares.
According to the Form 6-K, MNDR joined the framework on April 30. Hector Capital has room to invest as much as US$119 million, but the precise deal structure is not locked in yet; options on the table include equity, convertible instruments—securities that could become shares—or other financing methods.
The company said funds raised would be used for the planned BIMA and M&M Helix deals, plus general corporate and operating needs. Any acquisition price has to match an independent valuation, and the deal is still subject to both Nasdaq listing requirements and Singaporean law.
BIMA, launched in 2010, runs a health platform spanning Asia and Africa, covering everything from remote doctor consultations and specialist appointments to medicine delivery, lab work, and insurance. Singapore’s M&M Helix, on the other hand, is focused on healthcare tech, building an AI-driven telemedicine platform—here, telemedicine refers to care provided digitally via video, chat, or similar tools instead of traditional in-person visits.
Dr. Siaw Tung Yeng, MNDR’s co-CEO, called the framework a move that “sets the stage for transformative growth.” For Hector Capital, Vikash described the deal as proof of “confidence in MNDR’s vision.” TMX Newsfile
MNDR’s latest acquisition drive drops the company into an already packed digital-health arena, where bigger U.S.-listed rivals have a head start. Teladoc Health’s first-quarter 2026 revenue landed at $613.8 million, slipping 2% from last year. Hims & Hers, for its part, touts a platform that links patients with licensed healthcare pros and handles online pharmacy orders.
MNDR’s fresh announcement follows an April 28 deal with Dato’ Stanley Ling, who’s set to inject MYR 500 million—roughly US$126 million—into a planned 60 MW AI data-center campus in Sarawak, Malaysia. The structure: MNDR is expected to issue about 9 million Class A shares at US$14.10 apiece. Once everything’s finalized, Ling would end up with a 65% economic stake, but the founders hang onto majority voting rights via Class B shares.
As of Dec. 31, 2025, MNDR reported cash and equivalents of US$3.48 million, climbing from US$1.03 million at June 30, 2025. The company posted US$3.95 million in revenue for the half-year ended Dec. 31. Net loss shrank to US$858,417, compared to US$1.66 million for the same period last year.
The risk is clear enough. MNDR called the Hector Capital framework “strictly non-binding,” emphasizing that any deal would still hinge on due diligence, final investment and share-purchase agreements, independent valuation, and clearing all regulatory hurdles. Equity or convertible funding would also mean possible dilution for current holders. TMX Newsfile
Should the BIMA and M&M Helix transactions go through, MNDR stands to expand its reach in emerging-market healthcare—well beyond Singapore. If those deals fall apart, though, the company sticks with current financing, keeps tightening costs, and pushes ahead with its shift to AI-focused healthcare and infrastructure.
